Ponatinib in plasma BY LC-MS/MS

Ponatinib in plasma by  LC-MS/MS  (code  LC99010)  100 test package.

INSIGHTS
Ponatinib (Iclusig®), has been approved for the treatment of patients with Chronic Myeloid Leukemia (CSF) in the chronic, accelerated or blastic phase, resistant or intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or in whom the T315I mutation has been identified. Unfortunately, the clinical use of ponatinib is limited by the possible occurrence of occlusive vascular events (thrombosis and arterial and venous occlusions, including fatal myocardial infarction, stroke, stenosis of the large arterial vessels of the brain, severe peripheral vasculopathy). The Eureka Lab Division diagnostic KIT allows to constantly monitor the plasma concentrations of ponatinib during the therapy of each individual patient. Therefore, it represents for clinicians an important support tool, able to guarantee them the possibility of avoiding excessive plasma exposure to ponatinib that could cause thrombotic events.

Principle of the  Method:

Ponatinib is analysed by treating the plasma with a suitable deproteinization reagent. The solution is directly injected into LC/MS.

	IFU
	IFU MOBILE PHASE M1
	IFU MOBILE PHASE M2